Stockpolly
Search
Delisting risk
VYNE · NASDAQ · Biotechnology

VYNE Therapeutics (VYNE)

Develops BET inhibitor therapies for inflammatory and immune-mediated diseases.

$28.56
At close0.00 (0.00%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000001
Cost of revenue000000000000
Gross profit000000000001
6771113139885430
Research & development334710106553119
3443333332311
General & administrative0043333332311
Operating income−6−7−7−10−13−13−9−8−8−5−4−30
011111120003
Other non-operating income0−1−1−1−1−1−1−20000
Income before tax−6−6−6−9−12−12−9−6−7−5−4−27
Income tax expense000000000000
Net income from continuing operations−6−6−6−9−12−12−9−6−7−5−4−27
Discontinued operations−100000000000
Net income−7−6−6−9−12−12−9−6−7−5−4−26
EPS, basic−$2.01−$10.00−$7.50−$11.00−$14.50−$14.00−$10.00−$6.50−$8.50−$5.00−$4.19−$619.29
EPS, diluted−$2.01−$10.00−$7.50−$11.00−$14.50−$14.00−$10.00−$6.50−$8.50−$5.00−$4.19−$619.29
Weighted average shares, basic311111111110
Weighted average shares, diluted311111111110
EBITDA−6−6−6−8−12−12−9−6−7−5−4−30
Depreciation & amortization000100000000
EBIT−6−6−6−9−12−12−9−6−7−5−4−30